semaglutide and kidney disease in Diabetic Disease: Integrating Clinical Evidence with Mechanistic Insights semaglutide and chronic kidney disease

- July 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") , a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate

It suggests that the same hormonal systems that regulate hunger and energy balance also play a pivotal role in craving, impulse control, and emotional regulation

Creation of a Level 6 Neurostimulator APC In prior rulemaking, some interested parties have requested that we create a Level 6 Neurostimulator and Related Procedures APC, due to their concerns around clinical and resource cost similarity in the Level 5 Neurostimulator and Related Procedures APC

Centella Asiatica Complex: Gentle hydration meets targeted skin repair with leaf water and active molecules from Centella